Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 10/20 | 0.54 |
| ▸ | MMP9 | P14780 | 8/20 | 0.54 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP7 | P09237 | 1/20 | 0.49 |
| ▸ | HPN | P05981 | 1/20 | 0.48 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.48 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414097 | 1.00 | MMP3 (0.66) | MMP3MEN1KMT2AL3MBTL1MMP2 | |
| SCHEMBL6418278 | 0.94 | MMP3 (0.70) | MMP3MMP2MMP9ADAMTS4MMP13 | |
| SCHEMBL4431389 | 0.94 | MMP3 (0.70) | MMP3MMP2MMP9ADAMTS4MMP13 | |
| SCHEMBL4431378 | 0.94 | MMP3 (0.70) | MMP3MMP2MMP9ADAMTS4MMP13 | |
| SCHEMBL27560996 | 0.90 | MEN1 (0.65) | MMP3MEN1KMT2AL3MBTL1MMP2 | |
| SCHEMBL6416265 | 0.89 | MMP3 (0.60) | MMP3MMP2MMP9ADAMTS4MMP13 | |
| SCHEMBL6416258 | 0.89 | MMP3 (0.60) | MMP3MMP2MMP9ADAMTS4MMP13 | |
| SCHEMBL6418156 | 0.88 | MMP2 (0.65) | MMP3MEN1KMT2AL3MBTL1MMP2 | |
| SCHEMBL6418149 | 0.88 | MMP2 (0.65) | MMP3MEN1KMT2AL3MBTL1MMP2 | |
| SCHEMBL6419780 | 0.85 | MMP3 (0.67) | MMP3MMP2MMP9ADAMTS4MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0874836-B1 | SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2002-10-09 | — | — | EP | claimed |
| US-5977141-A | Sulfonamide inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 1999-11-02 | — | — | US | claimed |
| EP-0874836-A1 | SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-11-04 | — | — | EP | claimed |
| WO-1997019068-A1 | SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1997-05-29 | — | — | WO | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-0874836-B1 | SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6297247-B1 | Sulfonamide inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2001-10-02 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| US-5977141-A | Sulfonamide inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0874836-A1 | SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1997019068-A1 | SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP3 3/4885MEN1 3585/4885KMT2A 1629/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP3 3/4885MEN1 3585/4885KMT2A 1629/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP3 3/4885MEN1 3585/4885KMT2A 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.